A new infant immunization for respiratory syncytial virus (RSV), nirsevimab, is now available in Canada but must be purchased out of pocket in British Columbia, costing $800 to $900. While most provinces offer it free for all infants, B.C. only covers it for some high-risk infants, prompting calls from parents and doctors for universal access. Experts argue that broader coverage could reduce hospitalizations and overall healthcare costs. The B.C. Ministry of Health is reviewing eligibility criteria, with hopes for expanded access in the future.
